Walk Back Those Walking Claims, FDA Tells Acorda And Valeant
This article was originally published in The Pink Sheet Daily
Executive Summary
In separate “notice of violation” letters sent the same day to Acorda and Valeant, FDA stresses the limits of what companies can do with patient testimonials in web videos.
You may also be interested in...
Pharma Social Media Sites Struggle For Audience Under Shadow Of Potential FDA Action
Drug makers are using YouTube videos and other social media channels to broadcast their expertise and initiatives; Amgen differentiates its biologic manufacturing from biosimilars, J&J teams up with Huffington Post to tell stories about motherhood, and Pfizer tries to conduct a clinical trial online.
Auspex Secures $25M To Get To NDA
The biotech garnered a $25 million Series D round, which could be enough to propel it through a Phase III trial and to FDA with its lead candidate. Investors are hoping an approved product could make Auspex an attractive take-out candidate.
Valeant Racks Up FDA Letters Criticizing Its Promotional Materials
FDA says Valiant’s webpage for Zovirax overstates the efficacy of the herpes drug and makes unsubstantiated claims it is superior to Valtrex. It is the fifth letter the agency has sent the company in the past year.